Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03798639 · ClinicalTrials.gov registry record · Phase 1

Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer

A Phase 1 study of Merkel Cell Carcinoma and Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, sponsored by Claire Verschraegen.

Completed
Registry status
Phase 1
Development phase
7
Enrollment target
1
Study location

NCT03798639 is a Phase 1 study of Merkel Cell Carcinoma and Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8 that has completed, run by Claire Verschraegen. The registered enrollment target is 7 participants, below the 51-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03798639, a Phase 1 study of Merkel Cell Carcinoma and Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, has completed, sponsored by Claire Verschraegen.

COMPLETED
Registry status
Phase 1
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the side effects and how well nivolumab works when given together with radiation therapy or ipilimumab as adjuvant therapy in treating patients with Merkel cell cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons or other sources to kill tumor cells and shrink tumors. Giving nivolumab with radiation therapy or ipilimumab after surgery may kill any remaining tumor cells.

Conditions Studied

Merkel Cell Carcinoma Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8 Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8

Interventions

  • RADIATION Radiation Therapy
  • BIOLOGICAL Nivolumab
  • BIOLOGICAL Ipilimumab

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2019-01-07
Est. Completion 2022-12-02
Phase Phase 1

Sponsor

Claire Verschraegen

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03798639

The ClinicalTrials.gov registry entry for NCT03798639 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 51-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target (86% lower). The listed sponsor is Claire Verschraegen, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Merkel Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Radiation Therapy is the first listed.

NCT03798639 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03798639 about?

NCT03798639 is a clinical study titled "Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer". This phase I trial studies the side effects and how well nivolumab works when given together with radiation therapy or ipilimumab as adjuvant therapy in treating patients with Merkel cell cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body?s immune s...

What is the current status of trial NCT03798639?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2019-01-07. Estimated completion is 2022-12-02.

What conditions does trial NCT03798639 study?

This clinical trial studies the following conditions: Merkel Cell Carcinoma, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8.

What interventions are being tested in trial NCT03798639?

The interventions under investigation include: Radiation Therapy (RADIATION), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT03798639?

This trial is sponsored by Claire Verschraegen, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03798639 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Merkel Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Merkel Cell Carcinoma

All registered trials for this condition

Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.